Asian Pacific Journal of Cancer Prevention

  • 제17권3호
  • /
  • Pages.1103-1110
  • /
  • 2016
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Effects of a Multikinase Inhibitor Motesanib (AMG 706) Alone and Combined with the Selective DuP-697 COX-2 Inhibitor on Colorectal Cancer Cells

  • Kaya, Tijen Temiz (Department of Pharmacology, Faculty of Pharmacy, Cumhuriyet University) ;
  • Altun, Ahmet (Department of Pharmacology, Faculty of Pharmacy, Cumhuriyet University) ;
  • Turgut, Nergiz Hacer (Department of Gastroenterology, Faculty of Pharmacy, Cumhuriyet University) ;
  • Ataseven, Hilmi (Department of Pharmacology, Faculty of Pharmacy, Cumhuriyet University) ;
  • Koyluoglu, Gokhan (Department of Pediatric Surgery, Faculty of Medicine, Cumhuriyet University)
  • 발행 : 2016.04.11
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

In the present study, we investigated the effects of motesanib (AMG 706), a multikinase inhibitor alone and in combination with DuP-697, an irreversible selective inhibitor of COX-2, on cell proliferation, angiogenesis, and apoptosis induction in a human colorectal cancer cell line (HT29). Real time cell analysis (RTCA, Xcelligence system) was used to determine the effects on colorectal cancer cell proliferation. Apoptosis was assessed with annexin V staining and angiogenesis was determined with chorioallantoic membrane model. We found that motesanib alone exerted antiproliferative, antiangiogenic and apoptotic effects on HT29 colorectal cancer cells. Combination with DUP-697 increased the antiproliferative, antiangiogenic and apoptotic effects. Results of this study indicate that motesanib may be a good choice in treatment of colorectal tumors. In addition, the increased effects of combination of motesanib with DuP-697 raise the possibility of using lower doses of these drugs and therefore avoid/minimize the dose-dependent side effects generally observed.

키워드

참고문헌

  1. Agarwal V, Hodgkinson VC, Eagle GL, et al (2013). Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697. Int J Oncol, 42, 1088-92. https://doi.org/10.3892/ijo.2013.1784
  2. Altun A, Turgut NH, Kaya TT (2014).Anticancer effect of COX-2 inhibitor DuP-697 alone and in combination with tyrosine kinase inhibitor (E7080) on colon cancer cell lines. Asian Pac J Cancer Prev, 15, 3113-21. https://doi.org/10.7314/APJCP.2014.15.7.3113
  3. Bestas R, Kaplan MA, Isikdogan A (2014). The correlation between serum VEGF levels and known prognostic risk factors in colorectal carcinoma. Hepatogastroenterol, 61, 267-71.
  4. Agarwal V, Hodgkinson VC, Eagle GL, et al (2013). Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697. Int J Oncol, 42, 1088-92. https://doi.org/10.3892/ijo.2013.1784
  5. Blumenschein GR Jr, Kabbinavar F, Menon H, et al (2011). Motesanib NSCLC Phase II Study Investigators. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol, 22, 2057-67. https://doi.org/10.1093/annonc/mdq731
  6. Burgermeister J, Paper DH, Vogl H, et al. (2002) LAPSvS1, a ($1{\rightarrow}3$)-betagalactan sulfate and its effect on angiogenesis in vitro andin vivo. Carbohydr Res, 337, 1459-66. https://doi.org/10.1016/S0008-6215(02)00163-5
  7. Cathcart MC, O’Byrne KJ, Reynolds JV, O’Sullivan J, Pidgeon GP (2012). COX-derived prostanoid pathways in gastrointestinal cancer development and progression: novel targets for prevention and intervention. Biochim Biophys Acta, 1825, 49-63.
  8. Center M.M, Jemal A, Ward E (2009). International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev, 18, 1688-94. https://doi.org/10.1158/1055-9965.EPI-09-0090
  9. Chu E (2012). An update on the current and emerging targeted agents in metastatic colorectal. Cancer, 11, 1-13.
  10. Chu J, Lloyd FL, Trifan OC, Knapp B, Rizzo MT (2003). Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer. Mol Cancer Ther, 2, 1-7.
  11. Coxon A, Bush T, Saffran D, et al (2009). Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors. Clin Cancer Res, 15, 110-8. https://doi.org/10.1158/1078-0432.CCR-08-1155
  12. Coxon A, Ziegler B, Kaufman S, et al (2012) a. Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models. Mol Cancer, 11, 70. https://doi.org/10.1186/1476-4598-11-70
  13. Coxon A, Bready J, Kaufman S, et al (2012) b. Anti-tumor activity of motesanib in a medullary thyroid cancer model. J Endocrinol Invest, 35, 181-90.
  14. Cui Y, Deming-Halverson SL, Shrubsole MJ, et al (2014). Use of nonsteroidal anti-inflammatory drugs and reduced breast cancer risk among overweight women. Breast Cancer Res Treat, 146, 439-46 https://doi.org/10.1007/s10549-014-3030-7
  15. De Boer RH, Kotasek D, White S, et al (2012). Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer. Breast Cancer Res Treat, 135, 241-52. https://doi.org/10.1007/s10549-012-2135-0
  16. Demirci B, Dadandi MY, Paper DH, et al (2003). Chemical composition of the essential oil of Phlomis linearis Boiss.&Bal., and biologicaleffects on the CAM assay: a safety evaluation. Z Naturforsch C, 58, 826-9.
  17. Hohla F, Winder T, Greil R, et al 2014. Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives. World J Gastroenterol, 20, 6102-12. https://doi.org/10.3748/wjg.v20.i20.6102
  18. Kim BH, Kim CI, Chang HS, et al (2011). Cyclooxygenase-2 overexpression in chronic inflammation associated with benign prostatic hyperplasia: is it related to apoptosis and angiogenesis of prostate cancer? Korean J Urol, 52, 253-9. https://doi.org/10.4111/kju.2011.52.4.253
  19. Kim JY, Chung SW, Kim SY, Byun Y (2015). Enhanced Anti-Angiogenic Effect of Low Molecular Weight Heparin-Bile Acid Conjugates by Co-Administration of a Selective COX-2 Inhibitor. Pharm Res, 32, 2318-27. https://doi.org/10.1007/s11095-015-1623-4
  20. Li M, Tan SY, Wang XF (2014). Paeonol exerts an anticancer effect on human colorectal cancer cells through inhibition of $PGE{\geq}$ synthesis and COX-2 expression. Oncol Rep, 32, 2845-53. https://doi.org/10.3892/or.2014.3543
  21. Lu JF, Claret L, Sutjandra L et al (2010).Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients. Cancer Chemother Pharmacol, 66, 1151-8 https://doi.org/10.1007/s00280-010-1456-0
  22. Ma L, del Soldato P, Wallace JL (2002). Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance. Proc Natl Acad Sci U S A. 99, 13243-7. https://doi.org/10.1073/pnas.202392199
  23. Ninomiya I, Nagai N, Oyama K, et al (2012). Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum. Oncol Rep, 28, 777-84. https://doi.org/10.3892/or.2012.1885
  24. Ohno S, Ohno Y, Suzuki N, Soma G, Inoue M (2007). Cyclooxygenase-2 expression correlates with apoptosis and angiogenesis in endometrial cancer tissue. Anticancer Res, 27, 3765-70.
  25. Paudyal B, Paudyal P, Shah D, et al (2014). Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate. J Biomed Sci, 21, 35. https://doi.org/10.1186/1423-0127-21-35
  26. Roche Diagnostics GmbH (2008). Introduction of the RTCA SPInstrument. RTCA SP Instrument Operator's Manual, A. Acea Biosciences, 2008, 14-6.
  27. Qiu ZQ, Qiu ZR (2015). Sensitivity of gastric cancer cells to chemotherapy drugs in elderly patients and its correlation with cyclooxygenase-2 expression. Asian Pac J Cancer Prev, 16, 3447-50. https://doi.org/10.7314/APJCP.2015.16.8.3447
  28. Peng HL, Zhang GS, Liu JH, Gong FJ, Li RJ (2008).Dup-697, a specific COX-2 inhibitor, suppresses growth and induces apoptosis on K562 leukemia cells by cell-cycle arrest and caspase-8 activation. Ann Hematol, 87, 121-9. https://doi.org/10.1007/s00277-007-0385-4
  29. Riaz SK, Iqbal Y, Malik MF (2015). Diagnostic and therapeutic implications of the vascular endothelial growth factor family in cancer. Asian Pac J Cancer Prev, 16, 1677-82. https://doi.org/10.7314/APJCP.2015.16.5.1677
  30. Rosen LS, Kurzrock R, Mulay M, et al (2007). Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol, 25, 2369-76. https://doi.org/10.1200/JCO.2006.07.8170
  31. Saleem TH, Attya AM, Ahmed EA, et al (2015). Possible Protective Effects of Quercetin and Sodium Gluconate Against Colon Cancer Induction by Dimethylhydrazine in Mice. Asian Pac J Cancer Prev, 16, 5823-8. https://doi.org/10.7314/APJCP.2015.16.14.5823
  32. Salimi M, Esfahani M, Habibzadeh N, et al (2012). Change in nicotine-induced VEGF, PGE2 AND COX-2 expression following COX inhibition in human oral squamous cancer. J Environ Pathol Toxicol Oncol, 31, 349-56. https://doi.org/10.1615/JEnvironPatholToxicolOncol.2013005365
  33. Salinas CA, Kwon EM, FitzGerald LM, et al (2010). Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am J Epidemiol, 172, 578-90. https://doi.org/10.1093/aje/kwq175
  34. Saraiva AL, Payan-Carreira R, Gartner F, et al (2015). Immunohistochemical expression of cyclooxygenase-2 (COX-2) in feline endometrial adenocarcinoma and in normal and hyperplastic endometria. Reprod Domest Anim, 50, 333-40. https://doi.org/10.1111/rda.12497
  35. Schilder RJ, Sill MW, Lankes HA, et al (2013). A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol, 129, 86-91. https://doi.org/10.1016/j.ygyno.2013.01.006
  36. Steinbach G, Lynch PM, Phillips RK, et al (2000). The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med, 342, 1946-52. https://doi.org/10.1056/NEJM200006293422603
  37. Shimizu K, Yukawa T, Okita R, et al (2015). Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy. World J Surg Oncol, 13, 21. https://doi.org/10.1186/s12957-014-0426-0
  38. Tan HK, Moad AI, Tan ML (2014). The mTOR signalling pathway in cancer and the potential mTOR inhibitory activities of natural phytochemicals. Asian Pac J Cancer Prev, 15, 6463-75. https://doi.org/10.7314/APJCP.2014.15.16.6463
  39. Tebbutt N, Kotasek D, Burris HA, et al (2015). Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. Cancer Chemother Pharmacol, 75, 993-1004. https://doi.org/10.1007/s00280-015-2694-y
  40. Tu B, Ma TT, Peng XQ, et al (2014). Targeting of COX-2 expression by recombinant adenovirus shRNA attenuates the malignant biological behavior of breast cancer cells. Asian Pac J Cancer Prev, 15, 8829-36. https://doi.org/10.7314/APJCP.2014.15.20.8829
  41. van de Velde CJ, Boelens PG, Tanis PJ, et al (2014). Experts reviews of the multidisciplinary consensus conference colon and rectal cancer 2012: science, opinions and experiences from the experts of surgery. Eur J Surg Oncol, 40, 454-68. https://doi.org/10.1016/j.ejso.2013.10.013
  42. Wei D, Wang L, He Y, et al (2004). Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res, 64, 2030-8. https://doi.org/10.1158/0008-5472.CAN-03-1945
  43. Wong VW, Chan FK (2007). Aspirin reduced the incidence of colorectal cancer during 23-year follow-up in healthy men or patients with recent TIA. ACP J Club, 147, 72.
  44. Yazawa K, Tsuno NH, Kitayama J, et al (2005). Selective inhibition of cyclooxygenase (COX)-2 inhibits endothelial cell proliferation by induction of cell cycle arrest. Int J Cancer, 113, 541-8. https://doi.org/10.1002/ijc.20621
  45. Zhu LM, Zhao YZ, Ju HX, et al (2014). Efficacy and safety of bevacizumab in Chinese patients with metastatic colorectal cancer. Asian Pac J Cancer Prev, 15, 6559-64. https://doi.org/10.7314/APJCP.2014.15.16.6559